A treatment pioneered at the University of Pittsburgh Center for Vaccine Research (CVR) is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called “superbugs” resistant to almost all existing antibiotics, which plague hospitals and nursing homes.
The findings, announced online in the journal Antimicrobial Agents and Chemotherapy and funded by the National Institutes of Health, provide a needed boost to the field of antibiotic development, which has been limited in the last four decades and outpaced by the rise of drug-resistant bacterial strains.
“Very few, if any, medical discoveries have had a larger impact on modern medicine than the discovery and development of antibiotics,” said senior author Ronald C. Montelaro, Ph.D., professor and co-director of Pitt’s CVR. “However, the success of these medical achievements is being threatened due to increasing frequency of antibiotic resistance. It is critical that we move forward with development of new defenses against the drug-resistant bacteria that threaten the lives of our most vulnerable patients.”
Each year in the U.S., at least 2 million people are infected with drug-resistant bacteria, and at least 23,000 die as a direct result of these infections, according to the U.S. Centers for Disease Control and Prevention.
On the tail end of HIV surface protein, there is a sequence of amino acids that the virus uses to “punch into” and infect cells. Dr. Montelaro and his colleagues developed a synthetic and more efficient version of this sequence – called engineered cationic antimicrobial peptides, or “eCAPs”—that can be chemically synthesized in a laboratory setting.< The team tested the two leading eCAPs against a natural antimicrobial peptide (LL37) and a standard antibiotic (colistin), the latter being used as a last-resort antibiotic against multidrug resistant bacterial infections. The scientists performed the tests in a laboratory setting using 100 different bacterial strains isolated from the lungs of pediatric cystic fibrosis patients of Seattle Children’s Hospital and 42 bacterial strains isolated from hospitalized adult patients at UPMC.
The natural human antimicrobial peptide LL37 and the colistin drug each inhibited growth of about 50 percent of the clinical isolates, indicating a high level of bacterial resistance to these drugs. In marked contrast, the two eCAPS inhibited growth in about 90 percent of the test bacterial strains.
The Latest on: Antibiotic-Resistant Superbugs
via Google News
The Latest on: Antibiotic-Resistant Superbugs
- Viruses to Fight Superbugs? Scientists Are Working on Iton September 26, 2022 at 4:00 am
Phages may help fight drug-resistant infections—but finding the right ones for each bacterium is no mean feat.
- Record number of CPE superbug cases detected in Irish hospitals last monthon September 25, 2022 at 9:25 am
A record number of hospital patients were diagnosed with the potentially lethal CPE superbug last month. A total of 109 new CPE patients were identified in August, the highest level of detections ...
- Congress needs to fix the antibiotic marketon September 25, 2022 at 7:30 am
The views expressed by contributors are their own and not the view of The Hill The market for new antibiotics is broken, and that’s a problem because our current ones are failing. Almost any ...
- Little-known STI linked to infertility may become superbug, doctors worryon September 25, 2022 at 6:00 am
A little-known STI, mycoplasma genitalium, may be more common than thought. Doctors urge more research and testing.
- Nanoparticles show promise in defeating antibiotic-resistant bacteria, U of T researchers findon September 25, 2022 at 3:40 am
A new therapy developed by researchers at the University of Toronto may bring us one step closer to effectively killing deadly drug-resistant superbugs.“The threat posed by pathogens that are increasi ...
- Doctors urge more research into little-known STI linked to infertility in men and womenon September 25, 2022 at 3:00 am
Doctors are urging more research into a little-known sexually transmitted infection that may be more common than thought. Scientists have known for decades about mycoplasma genitalium, or M.
- New engineered peptides could prevent the superbug crisison September 22, 2022 at 8:17 pm
Yet, despite the efficacy of these antibiotics, there remains an urgent need for new and effective antimicrobial agents that can effectively combat antibiotic-resistant microorganisms. Naturally ...
- A drug that can kill antibiotic-resistant bacteria could stave off the coming superbug crisison September 20, 2022 at 12:00 pm
Worse, climate change may also be making drug-resistant superbugs even deadlier. However, researchers may have recently made a breakthrough with a new drug called PLG0206, which has been ...
- Honey could replace antibiotics in fight against superbugson September 20, 2022 at 8:45 am
Honey should replace antibiotics as a treatment for wounds to combat superbugs, scientists have argued.The antimicrobial properties of honey have been recognise ...
- Superbug ‘pandemic’ stalks India as antibiotic resistance jumps 10pc in a yearon September 16, 2022 at 1:01 am
India faces a “pandemic” of superbugs, the country’s top public health experts have warned, as resistance to common antibiotics has jumped by 10 per cent in just one year In the fifth ...
via Bing News